510 related articles for article (PubMed ID: 33934221)
21. Tauopathies.
Hernández F; Avila J
Cell Mol Life Sci; 2007 Sep; 64(17):2219-33. PubMed ID: 17604998
[TBL] [Abstract][Full Text] [Related]
22. Tau isoform expression and phosphorylation in marmoset brains.
Sharma G; Huo A; Kimura T; Shiozawa S; Kobayashi R; Sahara N; Ishibashi M; Ishigaki S; Saito T; Ando K; Murayama S; Hasegawa M; Sobue G; Okano H; Hisanaga SI
J Biol Chem; 2019 Jul; 294(30):11433-11444. PubMed ID: 31171723
[TBL] [Abstract][Full Text] [Related]
23. SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion.
Yin X; Jiang X; Wang J; Qian S; Liu F; Qian W
J Alzheimers Dis; 2018; 61(2):561-570. PubMed ID: 29226865
[TBL] [Abstract][Full Text] [Related]
24. Dementia Therapy Targeting Tau.
Buee L
Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
[TBL] [Abstract][Full Text] [Related]
25. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.
Ercan-Herbst E; Ehrig J; Schöndorf DC; Behrendt A; Klaus B; Gomez Ramos B; Prat Oriol N; Weber C; Ehrnhoefer DE
Acta Neuropathol Commun; 2019 Dec; 7(1):192. PubMed ID: 31796124
[TBL] [Abstract][Full Text] [Related]
26. Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.
Almansoub HAMM; Tang H; Wu Y; Wang DQ; Mahaman YAR; Wei N; Almansob YAM; He W; Liu D
J Alzheimers Dis; 2019; 67(1):13-33. PubMed ID: 30507581
[TBL] [Abstract][Full Text] [Related]
27. Brain microRNAs dysregulation: Implication for missplicing and abnormal post-translational modifications of tau protein in Alzheimer's disease and related tauopathies.
Bazrgar M; Khodabakhsh P; Mohagheghi F; Prudencio M; Ahmadiani A
Pharmacol Res; 2020 May; 155():104729. PubMed ID: 32126270
[TBL] [Abstract][Full Text] [Related]
28. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.
Gallo JM; Noble W; Martin TR
Cell Mol Life Sci; 2007 Jul; 64(13):1701-14. PubMed ID: 17453144
[TBL] [Abstract][Full Text] [Related]
29. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
30. Post-translational modifications of tau protein.
Pevalova M; Filipcik P; Novak M; Avila J; Iqbal K
Bratisl Lek Listy; 2006; 107(9-10):346-53. PubMed ID: 17262986
[TBL] [Abstract][Full Text] [Related]
31. Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.
Wisely EV; Xiang YK; Oddo S
Hum Mol Genet; 2014 Aug; 23(15):4024-34. PubMed ID: 24626633
[TBL] [Abstract][Full Text] [Related]
32. "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Giasson BI
Mol Neurodegener; 2021 Jun; 16(1):37. PubMed ID: 34090488
[TBL] [Abstract][Full Text] [Related]
33. Amyloid-β peptide alteration of tau exon-10 splicing via the GSK3β-SC35 pathway.
Chen KL; Yuan RY; Hu CJ; Hsu CY
Neurobiol Dis; 2010 Nov; 40(2):378-85. PubMed ID: 20615469
[TBL] [Abstract][Full Text] [Related]
34. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer's disease and primary tauopathies.
Hart de Ruyter FJ; Morrema THJ; den Haan J; ; Twisk JWR; de Boer JF; Scheltens P; Boon BDC; Thal DR; Rozemuller AJ; Verbraak FD; Bouwman FH; Hoozemans JJM
Acta Neuropathol; 2023 Feb; 145(2):197-218. PubMed ID: 36480077
[TBL] [Abstract][Full Text] [Related]
36. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.
Combs B; Voss K; Gamblin TC
Biochemistry; 2011 Nov; 50(44):9446-56. PubMed ID: 21942206
[TBL] [Abstract][Full Text] [Related]
37. Distribution of tau hyperphosphorylation in canine dementia resembles early Alzheimer's disease and other tauopathies.
Abey A; Davies D; Goldsbury C; Buckland M; Valenzuela M; Duncan T
Brain Pathol; 2021 Jan; 31(1):144-162. PubMed ID: 32810333
[TBL] [Abstract][Full Text] [Related]
38. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
[TBL] [Abstract][Full Text] [Related]
39. Tau Exon 10 Inclusion by PrP
Lidón L; Llaó-Hierro L; Nuvolone M; Aguzzi A; Ávila J; Ferrer I; Del Río JA; Gavín R
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065232
[TBL] [Abstract][Full Text] [Related]
40. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies.
Luk C; Compta Y; Magdalinou N; Martí MJ; Hondhamuni G; Zetterberg H; Blennow K; Constantinescu R; Pijnenburg Y; Mollenhauer B; Trenkwalder C; Van Swieten J; Chiu WZ; Borroni B; Cámara A; Cheshire P; Williams DR; Lees AJ; de Silva R
J Neurochem; 2012 Nov; 123(3):396-405. PubMed ID: 22862741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
